Feb 25 (Reuters) - Gilead Sciences on Wednesday said its experimental single-tablet HIV treatment was generally well ...

A new, daily oral tablet that combines two current HIV treatment medications, bictegravir and lenacapavir (BIC/LEN), could ...

People who have lived with HIV long-term can need up to a dozen pills every day to suppress the virus. Results from a new ...

A phase 3 clinical trial, led by Professor Chloe Orkin of Queen Mary University of London, has shown that a new, daily oral tablet that combines two current HIV treatment medications – bictegravir and ...

Data from two studies presented at the Conference on Retroviruses and Opportunistic Infections support the use of a novel, ...

A single-pill treatment to suppress HIV proved as effective as existing therapies of up to 11 tablets daily, the latest advance in a scientific “golden age” for treating the virus even as rich ...

While there are fewer men living with HIV than women, data shows that more men die of Aids. Experts and organisations ...

A new, daily oral tablet that combines two current HIV treatment medications, bictegravir and lenacapavir (BIC/LEN), may be able to effectively replace more complicated HIV treatment regimens used by ...

Merck said a treatment it is developing for HIV-1 met its primary endpoint in three Phase 3 trials. The biopharmaceutical company said Wednesday the results add to growing evidence for ...

As GSK’s HIV unit ViiV Healthcare grapples with a new rival in the injectable HIV prevention and treatment field, the company is reinforcing the staying power of its long-acting treatment Cabenuva | ...

The emergency rule comes just one day before a planned hearing between the DOH and the AIDS Healthcare Foundation.

Zimbabwe's health authorities on Thursday began administering the long-acting HIV prevention drug lenacapavir, making the ...